How are ORIC straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ORIC straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 163.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$555.80 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a ORIC straddle?

The breakeven for the ORIC straddle priced on this page is roughly $5.43 and $16.57 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ORIC market-implied 1-standard-deviation expected move is approximately 46.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current ORIC implied volatility affect this straddle?

ORIC ATM IV is at 163.60% with IV rank near 25.16%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

ORIC Straddle Strategy

ORIC (ORIC Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance.

ORIC (ORIC Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $986.5M, a beta of 1.06 versus the broader market, a 52-week range of 7.23-14.93, average daily share volume of 1.9M, a public-listing history dating back to 2020, approximately 122 full-time employees. These structural characteristics shape how ORIC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.06 places ORIC roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a straddle on ORIC?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current ORIC snapshot

As of June 30, 2026, spot at $10.82, ATM IV 163.60%, IV rank 25.16%, expected move 46.90%. The straddle on ORIC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 52-day expiry.

Why this straddle structure on ORIC specifically: ORIC IV at 163.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a ORIC straddle, with a market-implied 1-standard-deviation move of approximately 46.90% (roughly $5.07 on the underlying). The 52-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ORIC expiries trade a higher absolute premium for lower per-day decay. Position sizing on ORIC should anchor to the underlying notional of $10.82 per share and to the trader's directional view on ORIC stock.

ORIC straddle setup

The ORIC straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ORIC near $10.82, the first option leg uses a $11.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ORIC chain at a 52-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ORIC shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$11.00	$2.85
Buy 1	Put	$11.00	$2.72

ORIC straddle risk and reward

Net Premium / Debit: -$557.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$555.80
Breakeven(s): $5.43, $16.57
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

ORIC straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on ORIC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$542.00
$2.40	-77.8%	+$302.87
$4.79	-55.7%	+$63.75
$7.18	-33.6%	-$175.38
$9.58	-11.5%	-$414.50
$11.97	+10.6%	-$460.37
$14.36	+32.7%	-$221.25
$16.75	+54.8%	+$17.88
$19.14	+76.9%	+$257.01
$21.53	+99.0%	+$496.13

When traders use straddle on ORIC

Straddles on ORIC are pure-volatility plays that profit from large moves in either direction; traders typically buy ORIC straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

ORIC thesis for this straddle

The market-implied 1-standard-deviation range for ORIC extends from approximately $5.75 on the downside to $15.89 on the upside. A ORIC long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ORIC IV rank near 25.16% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ORIC at 163.60%. As a Healthcare name, ORIC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ORIC-specific events.

ORIC straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ORIC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ORIC alongside the broader basket even when ORIC-specific fundamentals are unchanged. Always rebuild the position from current ORIC chain quotes before placing a trade.

Frequently asked questions

What is a straddle on ORIC?: A straddle on ORIC is the straddle strategy applied to ORIC (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ORIC stock trading near $10.82, the strikes shown on this page are snapped to the nearest listed ORIC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ORIC straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ORIC straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 163.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$555.80 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ORIC straddle?: The breakeven for the ORIC straddle priced on this page is roughly $5.43 and $16.57 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ORIC market-implied 1-standard-deviation expected move is approximately 46.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on ORIC?: Straddles on ORIC are pure-volatility plays that profit from large moves in either direction; traders typically buy ORIC straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current ORIC implied volatility affect this straddle?: ORIC ATM IV is at 163.60% with IV rank near 25.16%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.